Common use of Cash and Available for Sale Securities Clause in Contracts

Cash and Available for Sale Securities. The following table summarizes the Company’s cash and available-for-sale securities’ amortized cost and estimated fair value by significant investment category as of June 30, 2015, and December 31, 2014 (in thousands): Amortized Cost and Estimated Fair Value June 30, December 31, 2015 2014 Cash and cash equivalents: Cash $ 489 $ 304 Cash equivalents Money market mutual funds 2 1 Commercial paper — — Total cash equivalents 2 1 Total cash and cash equivalents 491 305 Short-term investments: Corporate bonds — — Certificates of deposit 23 123 Commercial paper 34 — Other commodities 6 6 Collateralized debt obligations — — Total short-term investments 63 129 Long-term investments: Certificates of deposit — — Total long-term investments — — Total cash, and cash equivalents, short-term and long-term investments $ 554 $ 434 The contractual maturities of cash equivalents and short-term investments at June 30, 2015, and December 31, 2014, were less than one year. There were no long-term investments at June 30, 2015 and December 31, 2014. The Company typically invests in highly rated securities and its policy generally limits the amount of credit exposure to any one issuer. When evaluating the investments for other-than-temporary impairment, the Company reviews such factors as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer, and the Company’s intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of the investment’s amortized cost basis. During the three months ended June 30, 2015 and 2014, the Company did not recognize any impairment charges on outstanding investments. As of June 30, 2015, the Company does not consider any of its investments to be other-than-temporarily impaired.

Cash and Available for Sale Securities. The following table summarizes the Company’s cash and available-for-sale securities’ amortized cost and estimated fair value by significant investment category as of June 30, 2015, and December 31, 2014 and 2013 (in thousands): Amortized Cost and Estimated Fair Value June 30, December 31, 2015 2014 2013 Cash and cash equivalents: Cash $ 489 304 $ 304 1,048 Cash equivalents Money market mutual funds 2 1 1,641 Commercial paper — — 100 Total cash equivalents 2 1 1,741 Total cash and cash equivalents 491 305 2,789 Short-term investments: Corporate bonds — — 501 Certificates of deposit 23 123 800 Commercial paper 34 — 500 Other commodities 6 6 — Collateralized debt obligations — — 1,301 Total short-term investments 63 129 3,102 Long-term investments: Certificates of deposit — — 154 Total long-term investments — — 154 Total cash, and cash equivalents, short-term and long-term investments $ 554 434 $ 434 6,045 Realized gains and realized losses were not significant for either of the years ended December 31, 2014 or 2013. As of December 31, 2014, unrealized loss on investments was $0.1 million. As of December 31, 2013, there was no significant unrealized loss on investments. The cost of all securities sold is based on the specific identification method. The contractual maturities of cash equivalents and short-term investments at June 30, 2015, and December 31, 2014, 2014 and 2013 were less than one year. There were no long-term investments at June 30, 2015 and December 31, 20142014.The contractual maturity of long-term investments was just over one year as of December 31, 2013. The Company typically invests in highly highly-rated securities securities, and its policy generally limits the amount of credit exposure to any one issuer. When evaluating the investments for other-than-temporary impairment, the Company reviews such factors as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer, and the Company’s intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of the investment’s amortized cost basis. During the three months years ended June 30December 31, 2015 2014 and 20142013, the Company did not recognize any impairment charges on outstanding investments. As of June 30December 31, 20152014, the Company does not consider any of its investments to be other-than-temporarily impaired.

Cash and Available for Sale Securities. The following table summarizes the Company’s cash and available-for-sale securities’ amortized cost and estimated fair value by significant investment category as of June 30, 2015, and December 31, 2014 and 2013 (in thousands): Amortized Cost and Estimated Fair Value June 30, December 31, 2015 2014 2013 Cash and cash equivalents: Cash $ 489 304 $ 304 1,048 Cash equivalents Money market mutual funds 2 1 1,641 Commercial paper — — - 100 Total cash equivalents 2 1 1,741 Total cash and cash equivalents 491 305 2,789 Short-term investments: Corporate bonds — — - 501 Certificates of deposit 23 123 800 Commercial paper 34 — - 500 Other commodities 6 6 - Collateralized debt obligations — — - 1,301 Total short-term investments 63 129 3,102 Long-term investments: Certificates of deposit — — - 154 Total long-term investments — — - 154 Total cash, and cash equivalents, short-term and long-term investments $ 554 434 $ 434 6,045 Realized gains and realized losses were not significant for either of the years ended December 31, 2014 or 2013. As of December 31, 2014, unrealized loss on investments was $0.1 million. As of December 31, 2013, there was no significant unrealized loss on investments. The cost of all securities sold is based on the specific identification method. The contractual maturities of cash equivalents and short-term investments at June 30, 2015, and December 31, 2014, 2014 and 2013 were less than one year. There were no long-term investments at June 30, 2015 and December 31, 20142014.The contractual maturity of long-term investments was just over one year as of December 31, 2013. The Company typically invests in highly highly-rated securities securities, and its policy generally limits the amount of credit exposure to any one issuer. When evaluating the investments for other-than-temporary impairment, the Company reviews such factors as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer, and the Company’s intent to sell, or whether it is more likely than not it will be required to sell the investment before recovery of the investment’s amortized cost basis. During the three months years ended June 30December 31, 2015 2014 and 20142013, the Company did not recognize any impairment charges on outstanding investments. As of June 30December 31, 20152014, the Company does not consider any of its investments to be other-than-temporarily impaired.